Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kyverna Therapeutics, Inc. ( (KYTX) ) has issued an announcement.
Kyverna Therapeutics announced the appointment of Marc Grasso, M.D., as its new Chief Financial Officer, effective June 30, 2025. Dr. Grasso brings over 25 years of experience in public company management, capital markets, and investment banking. He succeeds Ryan Jones, who will transition to a strategic advisor role to ensure a smooth handover. Dr. Grasso’s expertise is expected to support Kyverna’s growth and its mission to bring CAR T-cell therapy to market for autoimmune diseases. His appointment is seen as a strategic move to bolster the company’s financial and operational capabilities, as it accelerates its clinical development and commercialization efforts.
The most recent analyst rating on (KYTX) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Underperform.
Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company’s technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock’s performance.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company is advancing its lead CAR T-cell therapy candidate, KYV-101, through late-stage clinical development for conditions such as stiff person syndrome and myasthenia gravis, with ongoing trials for lupus nephritis and other autoimmune indications.
Average Trading Volume: 397,017
Technical Sentiment Signal: Buy
Current Market Cap: $141.8M
See more data about KYTX stock on TipRanks’ Stock Analysis page.